January 17, 2017: New research published in Archives of Dermatological Research shows that hyperhidrosis (excessive sweating) is more prevalent, severe, and socially debilitating than previously reported.
According to the report –
• 4.8% of the population live with severe excessive sweating (significantly more than the 2.8% previously reported).
• 75% of those with excessive sweating say the condition has negative impacts on their social life, well-being, and emotional and mental health.
“This new research shows that the number of people living with debilitating excessive sweating is nearly double previous estimates,” says Dr. David Pariser, International Hyperhidrosis Society co-founder and winner of the American Academy of Dermatology's highest award. "There is a clear and pressing need for more treatment options to give these people relief.”
To help address this need, 25 dermatology sites across the nation are participating in a large national clinical trial of an investigational topical treatment option. “We hope that by participating in this research,” says Dr. Pariser “we can make a real impact on hyperhidrosis care for today’s sufferers as well as tomorrow’s.”
The global non-profit, International Hyperhidrosis Society (www.SweatHelp.org), urges hyperhidrosis sufferers nationwide to consider participation in excessive sweating research.
“We are calling on our millions of brave and powerful hyperhidrosis sufferers to help further the treatment development desperately needed,” says International Hyperhidrosis Society Executive Director and Co-Founder, Lisa J Pieretti.
This study is sponsored by Brickell Biotech, a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases.
Potential study participants must be at least 18 years old and experience excessive underarm sweating. Visit our Participate in Research page for more information.
About the International Hyperhidrosis Society:
Founded in 2003 by an elite team of world-respected physicians in hyperhidrosis research, the International Hyperhidrosis Society is the only independent, non- profit, global organization that strives to improve quality of life for those affected by excessive sweating. Its mission is to reduce the symptoms, anxiety, and social stigma associated with excessive sweating by improving the information, support, and treatment available to the millions of children, teens, and adults affected by hyperhidrosis worldwide. Learn more at www.SweatHelp.org.
About Brickell Biotech:
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Its pipeline consists of five product candidates, including potential novel therapeutics for hyperhidrosis (excessive sweating), atopic dermatitis, allergic contact dermatitis, acne and psoriasis. Brickell’s management team and board of directors have extensive experience in product development, having served in leadership roles at several pharmaceutical and successful start-up companies. Its strategy is to leverage this experience to in-license, acquire, develop and commercialize products that Brickell believes can be successful in the dermatology marketplace. For more information, visit www.brickellbio.com.